BackScopus Biopharma Overview

Scopus Biopharma Receivables

Latest receivables for SCPS: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Scopus Biopharma Receivables History

Loading

Scopus Biopharma vs. peers: Receivables Comparison

Loading

Scopus Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Scopus Biopharma (SCPS) FAQ

Scopus Biopharma (SCPS) currently reports a receivables of $0 as of June 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Scopus Biopharma's receivables history and peer comparisons.

Scopus Biopharma's receivables changed from $0 to $0 (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Scopus Biopharma reported $0 in receivables as of June 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Scopus Biopharma, and consider following SCPS for alerts when major investors trade the stock.

Scopus Biopharma is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCPS with unrelated industries.